Overall, these findings highlight that COA6 overexpression in pancreatic cancer is linked to a broad suppression of key immune markers, which could potentially hinder the effectiveness of immune checkpoint inhibitors. This evidence concerns the gene COA6 and familial pancreatic carcinoma.